Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7652W HIGH $15.30
Volume
16.99 M
Value Traded
111.16 M
Short % Float
22.15%
+3.32%Week
+79.61%1 Month
+261.88%3 Month
+322.54%6 Month
-78.68%5 Year
-21.09%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.62 B
EPS (TTM)
-0.64
P/E Ratio
-
Ent. Value
6.32 B
Total Shares
452.92 M
Float Shares
393.41 M
Insiders
13.15%
Institutions
57.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IOVA Catalyst Timeline
Dated clinical, regulatory and corporate events for Iovance Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Iovance Biotherapeutics, Inc.
828Total events
15Upcoming
134Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Grant / FundingCorporate
Inducement stock options and RSUs covering up to 450,000 shares granted to new CMO
●Management ChangeCorporate
Noah Berkowitz appointed Chief Medical Officer, effective September 30, 2026
▲Fast Track DesignationLifileucelApprovedDesignation
FDA granted Fast Track Designation for Lifileucel in soft tissue sarcomas
Soft Tissue Sarcomassource ↗
▲Other Regulator MilestoneAmtagviApprovedEx-US Regulatory
TGA approved Amtagvi MAA in Australia
Advanced Melanomasource ↗
▲Enrollment UpdateLifileucelApprovedTrial
IOV-LUN-202 enrollment nearly complete in pivotal cohorts
Metastatic Non-Squamous NSCLCsource ↗
▲Trial InitiationLifileucelApprovedTrial
SARATOGA trial in UPS and DDLPS is underway
UPS and DDLPSsource ↗
▲Primary Endpoint MetLifileucelApprovedClinical Data
Positive initial data in IOV-END-201
Metastatic Serous Endometrial Cancersource ↗
●Protocol AmendmentLifileucelApprovedTrial
Protocol amendment for IOV-END-201 being submitted
Metastatic Serous Endometrial Cancersource ↗
◆FDA Feedback ReceivedLifileucelApprovedFDA Meeting
Engagement with FDA underway on expedited approval pathway
Metastatic Serous Endometrial Cancersource ↗
●Enrollment UpdateIOV-4001Trial
IOV-GM1-201 enrolling patients with previously treated metastatic melanoma and NSCLC
Metastatic Melanoma and NSCLCsource ↗
●Enrollment UpdateIOV-3001Trial
IOV-IL2-101 Phase 1 safety cohort advancing through dose levels
Solid Tumorssource ↗
●Trial InitiationIOV-4001Trial
IOV-GM1-201 trial enrolling patients
Metastatic Melanoma and NSCLCsource ↗
●Trial InitiationIOV-3001Trial
IOV-IL2-101 trial advancing through dose levels
TIL treatment regimensource ↗
▲Accelerated Approval PathwayLifileucelApprovedDesignation
Engaging FDA on expedited approval pathway for endometrial cancer
Metastatic Serous Endometrial Cancersource ↗
◆Trial InitiationIOV-5001Trial
Phase 1/2 basket trial of IOV-5001 to begin enrolling
advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, and other solid tumorssource ↗
●EU MAA SubmissionAmtagviApprovedEx-US Regulatory
UK MAA resubmitted to MHRA in early July
Advanced Melanomasource ↗
◆R&D DayPresentation
Iovance to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
▲Other Regulator MilestoneAmtagviApprovedEx-US Regulatory
TGA granted approval with conditions for Amtagvi in advanced melanoma
advanced melanomasource ↗
▲IND ClearanceIOV-5001IND
FDA clearance of IND for IOV-5001 Phase 1/2 basket trial
advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, and other solid tumorssource ↗
▲Topline ReadoutLifileucelApprovedClinical Data
40% confirmed objective response rate in metastatic serous endometrial cancer
metastatic serous endometrial cancersource ↗
▲Trial InitiationTrial
Registrational trial in advanced sarcomas now underway
advanced sarcomassource ↗
◆Trial InitiationLifileucelApprovedTrial
Plan to commence single arm registrational trial in second-line advanced UPS and DDLPS
second-line advanced UPS and DDLPSsource ↗
◆Enrollment CompleteLifileucelApprovedTrial
Enrollment completion expected for IOV-LUN-202
advanced nonsquamous non-small cell lung cancersource ↗
▲Fast Track DesignationLifileucelApprovedDesignation
FDA Fast Track Designation granted for Lifileucel in second-line advanced NSCLC
Second-Line Advanced Non-Small Cell Lung Cancersource ↗
▲Topline ReadoutLifileucelApprovedClinical Data
Positive early data from pilot trial of lifileucel in advanced UPS/DDLPS: 50% ORR in first six evaluable patients
advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS)source ↗
●Equity OfferingCorporate
Inducement stock options granted to two new non-executive employees
▲Oral PresentationAmtagviApprovedPresentation
Oral presentation of real-world Amtagvi data at 2026 Tandem Meetings
advanced melanomasource ↗
▲Full ResultsAmtagviApprovedClinical Data
Published final five-year analysis of C-144-01 trial
advanced melanomasource ↗
▲Interim AnalysisLifileucelApprovedTrial
Interim data from IOV-LUN-202 trial of lifileucel monotherapy in advanced nonsquamous NSCLC
advanced nonsquamous non-small cell lung cancersource ↗
▲Product LaunchAmtagviApprovedPost-Market
Authorization of first Canadian treatment center expected within next few months
advanced melanomasource ↗
▲FDA ApprovalAmtagviApprovedFDA Decision
FDA & Health Canada approval for Amtagvi in advanced melanoma
advanced melanomasource ↗
▲EU ApprovalAmtagviApprovedEx-US Regulatory
Health Canada approval (NOC/c) for Amtagvi in advanced melanoma
advanced melanomasource ↗
◆Other Regulator MilestoneAmtagviApprovedEx-US Regulatory
First ex-U.S. regulatory approval expected imminently
advanced melanomasource ↗
▼Short Report ActivistCorporate
Securities fraud class action filed; lead plaintiff deadline July 14, 2025
Past FDA Catalysts and PDUFA Decisions
How IOVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | IOV-5001 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C56 / 100
Pipeline Score
$1.5B
Pipeline Value
$1.4B
Commercial Value
Overvalued
Valuation Signal
8
Drugs Scored
0.3x
rNPV / MCap
Top 10%
Small Cap(rank 67 of 660)
Percentile Rank
Iovance Biotherapeutics, Inc. carries a moderate pipeline score (56/100), with $2.4B risk-adjusted pipeline value, led by LN-145 in Cutaneous Squamous Cell Carcinoma (Phase 2), across $64B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $325M x 4.4 = $1.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Amtagvi | $273M | $188M | +45.1% |
| Proleukin | $52M | $53M | -2.8% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LN-145 Monoclonal antibodyNCT04614103 | Metastatic Non Small Cell Lung Cancer | Phase 2 | RECRUITING | 170 | Dec 1, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every IOVA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| lifileucel PriorityFast TrackAccelerated+1 | advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma | 2026-02-24 | In a pilot clinical trial, lifileucel demonstrated a 50% objective response rate (ORR) in six evaluable patients with advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, all of whom were refractory to prior therapies.Read More | Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue SarcomasRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Vogt Frederick GDirector, Officer (Interim CEO & General Counsel) | Option | 15,626 602,085 held | $0.00 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IOVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Palo Alto Investors LP | 3 % (-11.8 %) | 22.03 M | 5.30 M | -16.59% ( -1.05 M) |
IOVA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IOVA ranks across every disease it competes in
Competitive Position is a premium feature
See how IOVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIOVA News
IOVAIovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Iovance Biotherapeutics has appointed Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, effective September 30, 2026. Berkowitz brings extensive experience in drug development, particularly in cancer therapies, and is expected to play a crucial role in advancing Iovance's tumor infiltrating lymphocyte (TIL) therapies. His previous achievements include leading successful FDA approvals and expanding clinical programs.
Read more →IOVA▲ +31.5%on this newsshared move
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Iovance Biotherapeutics has raised its full year 2026 revenue guidance to $410 to $420 million, reflecting strong U.S. demand for its products, Amtagvi and Proleukin. This increase of $55 million at the midpoint indicates a projected annual growth of nearly 60%. The company also reported record second quarter revenues and plans to expand its treatment center network.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced the grant of inducement stock options to 18 new employees, totaling 179,750 shares. The stock options, part of the company's 2021 Inducement Plan, have an exercise price of $10.02 and will vest over three years. This move reflects Iovance's commitment to expanding its workforce as it continues to innovate in cancer therapies.
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics will present at two upcoming conferences, showcasing its leadership in tumor infiltrating lymphocyte (TIL) therapies. The presentations will occur at the Wells Fargo Healthcare Conference on September 10, 2026, and the H.C. Wainwright Global Investment Conference on September 15, 2026. The company continues to innovate in cancer treatment with its FDA-approved therapy, Amtagvi®.
Read more →IOVA▲ +43.1%on this news
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Iovance Biotherapeutics reported a record revenue of approximately $99.3 million for Q2 2026, reflecting a 66% increase year-over-year. The company has received FDA Fast Track Designation for its product lifileucel in treating soft tissue sarcomas. Iovance is also reviewing its revenue guidance for the year based on strong demand trends and expanding clinical pipeline.
Read more →IOVAIovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
Iovance Biotherapeutics will report its second quarter 2026 financial results and corporate updates on August 6, 2026. The company focuses on developing tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. Investors can access the live and archived webcast through the company's website. Iovance aims to lead in innovative cancer therapies.
Read more →IOVA▼ -7.6%on this news
Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Iovance Biotherapeutics has received approval from the Therapeutic Goods Administration (TGA) in Australia for its T cell therapy, Amtagvi (lifileucel), to treat advanced melanoma. This is the first T cell therapy designated for solid tumors in the region, addressing a critical need given Australia's high incidence of melanoma. The approval is based on safety and efficacy results from the C-144-01 clinical trial and represents a key milestone for Iovance as it aims to establish a treatment center in Australia and expand to other markets.
Read more →IOVAIovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Iovance Biotherapeutics has received FDA clearance for its investigational new drug application for IOV-5001, a next-generation interleukin-12 tethered TIL therapy. The Phase 1/2 clinical trial is set to begin enrolling patients in the second half of 2026 and will focus on treating advanced colorectal, triple-negative, and estrogen receptor-low breast cancers among other solid tumor types. IOV-5001 is designed to deliver targeted therapeutic effects directly within the tumor, aiming to enhance treatment effectiveness while minimizing systemic toxicity.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 22, 2026
Iovance Biotherapeutics announced the grant of inducement stock options covering 93,340 shares to thirteen new non-executive employees. These options, part of the Amended and Restated 2021 Inducement Plan, have an exercise price of $3.70 and will vest over three years. This move reflects the company's commitment to attracting talent as it advances its TIL therapies for cancer treatment.
Read more →IOVAIovance Biotherapeutics to Present at Upcoming Conference
Iovance Biotherapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. Interim CEO Fred Vogt and CFO Corleen Roche will participate in a fireside chat. The event highlights Iovance's commitment to advancing tumor infiltrating lymphocyte therapies for cancer treatment.
Read more →IOVA▼ -13.2%on this news
Iovance Biotherapeutics Highlights Positive Results, Business Achievements and Corporate
Iovance Biotherapeutics has reported promising first-quarter results for 2026, with total revenue reaching approximately $71 million, marking a 45% year-over-year increase. The company has indicated strong revenue guidance for the second quarter, expecting to achieve between $86 million and $88 million. Key developments include encouraging clinical data for lifileucel in the treatment of metastatic serous endometrial cancer, along with ongoing efforts to enhance operational efficiency. Overall, Iovance is well-positioned for continued growth in the biopharma market.
Read more →IOVAIovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
Iovance Biotherapeutics will report its first quarter 2026 financial results and corporate updates on May 7, 2026. The company aims to lead in developing tumor infiltrating lymphocyte therapies for cancer. The conference call will be accessible via a live audio webcast, which will also be archived for one year.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - April 17, 2026
Iovance Biotherapeutics has granted inducement stock options for 135,470 shares to twelve new non-executive employees as part of its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $3.80 and vests over three years. This move reflects the company's commitment to expanding its workforce and advancing its innovative cancer therapies.
Read more →IOVAIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - March 20, 2026
Iovance Biotherapeutics announced the grant of inducement stock options covering 3,400 shares to a new employee, in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.87 and will vest over three years. This move reflects Iovance's commitment to attracting talent as it develops novel cancer therapies.
Read more →About Iovance Biotherapeutics, Inc.
Headquarters825 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
BIOPHARMAWATCH ELITE PLUS
Trade the next IOVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime